UnknownNot Applicable

Antiangiogenic Therapy of CNV Associated With Angioid Streaks

Ukraine100 participantsStarted 2018-03-27

Plain-language summary

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to angioid streaks.

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Able to read (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent form or a family member) and understand the informed consent form and willing to sign the informed consent form.
✓. Signed informed consent form.
✓. Men and women ≥ 18 years of age.
✓. Willing, committed, and able to return for all clinic visits and complete all study-related procedures.
✓. First diagnosed active subfoveal or juxtafoveal (within 1 to 199 μm of the center of the fovea) CNV secondary to angioid streaks as defined by leakage on FA
✓. Transparent optical media and possibility to mydriasis.
✓. Best corrected visual acuity at least 20/100 Equivalent of Snellen (ETDRS).

✕. Ocular media of insufficient quality to obtain fundus and OCT images in the study eye.
✕. Recurrent CNV in the study eye.
✕. History or presence of CNV with an origin other than angioid streaks in the study eye.
✕. Ocular inflammation or external ocular inflammation in the study eye. 5 Concurrent disease in the study eye that would compromise BCVA or require medical or surgical intervention during the study period.

Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Chart

Timeframe: Baseline-Month 12

NCT IDNCT04119219

SponsorThe Filatov Institute of Eye Diseases and Tissue Therapy

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-31

Andrii MD Korol, PhD

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Able to read (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent form or a family member) and understand the informed consent form and willing to sign the informed consent form.
✓. Signed informed consent form.
✓. Men and women ≥ 18 years of age.
✓. Willing, committed, and able to return for all clinic visits and complete all study-related procedures.
✓. First diagnosed active subfoveal or juxtafoveal (within 1 to 199 μm of the center of the fovea) CNV secondary to angioid streaks as defined by leakage on FA
✓. Transparent optical media and possibility to mydriasis.
✓. Best corrected visual acuity at least 20/100 Equivalent of Snellen (ETDRS).

✕. Ocular media of insufficient quality to obtain fundus and OCT images in the study eye.
✕. Recurrent CNV in the study eye.
✕. History or presence of CNV with an origin other than angioid streaks in the study eye.
✕. Ocular inflammation or external ocular inflammation in the study eye. 5 Concurrent disease in the study eye that would compromise BCVA or require medical or surgical intervention during the study period.